QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

TCMD

QT69Tactile Systems Technology, Inc.
NASDAQ·Healthcare·Medical - Devices·USA
Latest market price
26.62
+0.79+3.06%
OverviewShort InterestFilings
TCMDQT69Tactile Systems Technology, Inc.·NASDAQ
OverviewShort InterestFilings
26.62+3.06%
TA
Loading chart...
Screen all →
ABT-0.10%$88.41ISRG+1.14%$406.78SYK+2.21%$307.80MDT+1.54%$79.34BSX+0.76%$45.29EW+0.78%$87.36DXCM+1.74%$72.47RMD+1.26%$188.63
Snapshot
Index-P/E28.71EPS (ttm)0.88
Insider Own-
Shs Outstand-
Perf Week1.02%
Market Cap582.63MForward P/E17.01EPS next Y1.57Insider Trans-Shs Float-Perf Month9.73%
Enterprise Value522.81MPEG0.79EPS next Q0.14Inst Own-Short Float-Perf Quarter-1.66%
Income20.28MP/S1.70EPS this Y28.98%Inst Trans-Short Ratio-Perf Half Y-8.05%
Sales343.52MP/B2.67EPS next Y37.89%ROA7.46%Short Interest-Perf YTD-8.21%
Book/sh-P/C13.86EPS next 5Y40.17%ROE9.70%52W High37.77 -29.52%Perf Year171.36%
Cash/sh-P/FCF14.86EPS past 3/5Y-ROIC7.93%52W Low9.41 182.89%Perf 3Y-
Dividend Est.-EV/EBITDA12.59Sales past 3/5Y10.14% 12.03%Gross Margin75.68%Volatility2.13% 2.55%Perf 5Y-
Dividend TTM-EV/Sales1.52EPS Y/Y TTM25.71%Oper. Margin9.40%ATR (14)1.00Perf 10Y-
Dividend Ex-Date-Quick Ratio3.78Sales Y/Y TTM17.41%Profit Margin5.91%RSI (14)60.06Recom2.00
Dividend Gr. 3/5Y-Current Ratio4.24EPS Q/Q38.46%SMA204.47%Beta0.68Target Price39.25
Payout0.00%Debt/Eq0.07Sales Q/Q22.95%SMA507.67%Rel Volume1.36Prev Close25.83
Employees1,037LT Debt/Eq0.06EarningsAug 03SMA20011.03%Avg Volume301.07KPrice26.62
IPO DateJul 28, 2016Option/ShortYes / YesEPS/Sales Surpr.-14.29% 5.63%Net Debt/EBITDA-1.44Volume410,845Change3.06%
Analyst Ratings
DateActionAnalystRatingTarget
May-07-26UpgradeB. Riley SecuritiesNeutral → Buy
May-05-26ReiteratedBTIGBuy$38 → $40
Feb-18-26ReiteratedLake StreetBuy$32 → $40
Feb-18-26ReiteratedBTIGBuy$28 → $38
Feb-18-26ReiteratedPiper SandlerOverweight$35 → $42
Jan-05-26ReiteratedRaymond James$35
Jan-05-26UpgradePiper SandlerNeutral → Overweight$20 → $35
Nov-04-25ReiteratedPiper SandlerNeutral$14 → $20
Nov-04-25ReiteratedLake StreetBuy$24 → $32
Nov-04-25UpgradeBTIGNeutral → Buy$16 → $28
Latest News
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue344330293
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A848276
Gross Profit261248217
Selling, General and Administrative Excl. Other218210183
Research and Development1089
Other Operating Expense003
Operating Income322922
Interest Expense012
Unusual Expense
———
Non-Operating Income (Expense)-3-3-3
Net Income Before Taxes343123
Income Taxes14127
Consolidated Net Income201917
Net Income From Continuing Operations201917
Net Income201917
EPS (Recurring)0.900.830.71
EPS (Basic, Before Extraordinaries)0.900.830.71
EPS (Diluted)0.880.820.70
EBITDA423932
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio30.2535.37—
Price To Sales Ratio1.782.02—
Gross Margin75.8775.1574.06
Operating Margin9.308.797.51
Net Margin5.815.765.80
Shares Outstanding232324
Market Capitalization612667—
Operating Lease Expense
———
Insider Trading Volume
$28.15$26.00$23.84$21.69$19.54● Close Price0.00M0.36M0.72M1.08M1.43MUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Birkemeyer Elaine M.CHIEF FINANCIAL OFFICERMay 11 '26Sale24.494,631113,404130,188May 13 12:00 AM
Dodd Sheri LouiseChief Executive OfficerFeb 24 '26Sale28.9410,993318,144243,885Feb 26 12:00 AM
Birkemeyer Elaine M.CHIEF FINANCIAL OFFICERFeb 24 '26Sale28.947,701222,880134,819Feb 26 12:00 AM
Burns KristieSr. VP Mktg & Clinical AffairsFeb 24 '26Sale28.946,246180,76482,581Feb 26 12:00 AM
Birkemeyer Elaine M.CHIEF FINANCIAL OFFICERFeb 23 '26Sale28.305,518156,144142,520Feb 24 12:00 AM
Dodd Sheri LouiseChief Executive OfficerFeb 23 '26Sale28.3015,240431,245254,878Feb 24 12:00 AM
Burns KristieSr. VP Mktg & Clinical AffairsFeb 23 '26Sale28.304,439125,61288,827Feb 24 12:00 AM
Burns KristieSr. VP Mktg & Clinical AffairsJan 02 '26Sale28.855,139148,26072,401Jan 06 12:00 AM
Dodd Sheri LouiseChief Executive OfficerAug 08 '25Sale12.367,76295,907173,479Aug 12 12:00 AM
Birkemeyer Elaine M.Chief Financial OfficerMay 12 '25Sale9.942,92129,03799,111May 14 12:00 AM
Dodd Sheri LouiseChief Executive OfficerMay 08 '25Sale9.833,14930,955181,241May 12 12:00 AM
BURKE WILLIAM WDirectorMay 08 '25Sale9.673,30031,91148,520May 09 12:00 AM
Burns KristieSr. VP Mktg & Clinical AffairsFeb 25 '25Sale14.406,46893,16077,540Feb 27 12:00 AM
Birkemeyer Elaine M.Chief Financial OfficerFeb 25 '25Sale14.512,06629,980102,032Feb 27 12:00 AM
REUVERS DANIEL L.DirectorFeb 25 '25Sale14.1828,338401,850214,604Feb 27 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR